Physician profile
Sara Welsh
NPI 1689806119
$1,641.64
in general payments reported to CMS, 2019-2025
30 companies · $355 in 2025
The $355 reported for 2025 was more than what 88% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.43 · 2021: $106 · 2022: $257 · 2023: $497 · 2024: $412 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,263.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $275.15 | 2021-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $125.30 | 2021-2024 | Trintellix |
| Abbott Laboratories | $122.11 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $120.33 | 2022-2025 | |
| Novo Nordisk INC | $118.19 | 2023-2025 | Wegovy, Ozempic |
| Xeris Pharmaceuticals, INC. | $80.31 | 2024-2025 | Gvoke Hypopen |
| Pfizer INC. | $76.62 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $74.01 | 2022-2023 | Gardasil 9, Vaxneuvance, Vaxelis |
| Ironshore Pharmaceuticals INC. | $69.03 | 2020-2023 | Jornay Pm |
| Lilly USA, LLC | $62.65 | 2022-2024 | Jardiance, Zepbound |
| Neos Therapeutics, LP | $60.91 | 2023-2024 | Adzenys Xr-Odt |
| Glaxosmithkline, LLC. | $60.74 | 2023-2025 | Bexsero |
| Collegium Pharmaceutical, INC. | $58.28 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $35.87 | 2023-2025 | Qelbree, Tlando, Xyosted |
| Dexcom, INC. | $32.71 | 2023-2025 | Dexcom G6 Transmitter |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $29.10 | 2021-2023 | Doc Band |
| Exact Sciences Corporation | $23.29 | 2024 | Cologuard Collection Kit |
| Abbvie INC. | $22.28 | 2025 | |
| Mayne Pharma Commercial LLC | $20.52 | 2024 | |
| Lundbeck LLC | $19.38 | 2025 | Rexulti |
| Phadia US INC. | $19.27 | 2023 | Immunocap |
| Sanofi-Aventis U.S. LLC | $19.12 | 2024 | |
| Janssen Pharmaceuticals, INC | $17.84 | 2023 | Xarelto |
| Halozyme INC | $15.14 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.73 | 2024 | Farxiga |
| Vertical Pharmaceuticals, LLC | $14.15 | 2025 | Relexxii |
| Noven Therapeutics, LLC | $13.97 | 2023 | Xelstrym |
| Nestle Healthcare Nutrition INC. | $13.00 | 2023 | |
| Tris Pharma INC | $12.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Welsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.